Intec Pharma (NASDAQ:NTEC)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in a research report issued on Monday, March 12th. They presently have a $16.00 target price on the biotechnology company’s stock. HC Wainwright’s price objective points to a potential upside of 153.97% from the company’s previous close.
A number of other equities analysts also recently commented on NTEC. Oppenheimer set a $15.00 target price on shares of Intec Pharma and gave the stock a “buy” rating in a research note on Thursday, November 16th. ValuEngine downgraded shares of Intec Pharma from a “hold” rating to a “sell” rating in a research note on Thursday, November 16th. Maxim Group set a $8.00 price target on shares of Intec Pharma and gave the company a “buy” rating in a research note on Friday, November 17th. Finally, Zacks Investment Research raised shares of Intec Pharma from a “hold” rating to a “buy” rating and set a $7.00 price target on the stock in a research note on Wednesday, November 22nd. Two investment analysts have rated the stock with a sell rating and six have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $12.67.
NTEC stock traded down $0.20 during trading on Monday, reaching $6.30. 48,289 shares of the stock were exchanged, compared to its average volume of 99,274. Intec Pharma has a 1 year low of $4.80 and a 1 year high of $9.80. The company has a market capitalization of $166.88, a PE ratio of -3.82 and a beta of 1.26.
Several institutional investors have recently added to or reduced their stakes in the company. Meitav Dash Investments Ltd. purchased a new stake in shares of Intec Pharma in the 4th quarter valued at approximately $8,607,000. Sectoral Asset Management Inc acquired a new position in shares of Intec Pharma in the third quarter valued at approximately $3,177,000. Millennium Management LLC acquired a new position in shares of Intec Pharma in the fourth quarter valued at approximately $1,392,000. Renaissance Technologies LLC grew its holdings in shares of Intec Pharma by 66.0% in the fourth quarter. Renaissance Technologies LLC now owns 133,500 shares of the biotechnology company’s stock valued at $688,000 after purchasing an additional 53,100 shares in the last quarter. Finally, Deutsche Bank AG grew its holdings in shares of Intec Pharma by 59.2% in the fourth quarter. Deutsche Bank AG now owns 115,217 shares of the biotechnology company’s stock valued at $593,000 after purchasing an additional 42,867 shares in the last quarter. 41.39% of the stock is currently owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION NOTICE: “Intec Pharma’s (NASDAQ:NTEC) Buy Rating Reiterated at HC Wainwright” was first reported by BBNS and is the property of of BBNS. If you are accessing this piece of content on another domain, it was stolen and republished in violation of international copyright & trademark legislation. The original version of this piece of content can be accessed at https://baseballnewssource.com/2018/04/06/hc-wainwright-reaffirms-buy-rating-for-intec-pharma-ntec/2037219.html.
About Intec Pharma
Intec Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel. Its Accordion Pill is an oral drug delivery system that is designed to enhance the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism.
Receive News & Ratings for Intec Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intec Pharma and related companies with MarketBeat.com's FREE daily email newsletter.